Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
231.95
+0.90 (0.39%)
At close: Dec 12, 2025, 4:00 PM EST
232.00
+0.05 (0.02%)
After-hours: Dec 12, 2025, 7:56 PM EST
Natera Revenue
Natera had revenue of $592.18M in the quarter ending September 30, 2025, with 34.66% growth. This brings the company's revenue in the last twelve months to $2.12B, up 38.17% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$2.12B
Revenue Growth
+38.17%
P/S Ratio
14.79
Revenue / Employee
$477,374
Employees
4,434
Market Cap
32.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTRA News
- 2 days ago - Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer - Business Wire
- 3 days ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 4 days ago - Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer - Business Wire
- 5 days ago - Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting - Business Wire
- 9 days ago - Natera Acquires Foresight Diagnostics - Business Wire
- 11 days ago - New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting - Business Wire
- 12 days ago - Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium - Business Wire
- 14 days ago - 30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool